Hepatocellular carcinoma (HCC) is a complex biological process and is often diagnosed at
advanced stages with no effective treatment options. With advances in tumor biology and …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

Hepatocellular carcinoma is among the most lethal and prevalent cancers in the human
population. Despite its significance, there is only an elemental understanding of the …

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …

The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase
that is activated by several ligands leading to the activation of diverse signaling pathways …

Despite the recent introduction of new effective systemic agents, the survival of patients with
hepatocellular carcinoma (HCC) at advanced stages remains dismal. This underscores the …

Hepatocellular carcinoma (HCC) is a frequent cancer with limited treatment options and
poor prognosis. Tumorigenesis has been linked with macrophage-mediated chronic …

Dysregulation of pleiotropic growth factors, receptors and their downstream signaling
pathway components represent a central protumorigenic principle in human …

Hepatocellular carcinoma (HCC) is associated with a poor prognosis due to late diagnoses
and a lack of effective treatment options. Epidermal growth factor receptor (EGFR)–targeted …

Hepatocellular carcinoma is often diagnosed at an advanced stage, when it is not amenable
to curative therapies. There is no effective chemotherapy. Advances in cancer biology …